GlaxoSmithKline (GSK) filed for drug approval with the U.S. FDA at the end of 2002 and in January 2003 with the European Medicines Evaluation Agency (EMEA). In October 2003, the …

2003年6月25日 · Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor under development by GlaxoSmithKline Pharmaceuticals for treatment of COPD. After the demise of …

One of the most clinically advanced PDE4 inhibitors is cilomilast (Ariflo®, SB 207499), which is under development by GlaxoSmithKline (GSK) for the treatment of COPD. This compound is …

Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive …

2003年9月4日 · GlaxoSmithKline (LSE:GSK; GSK) is seeking approval of Ariflo to treat chronic obstructive pulmonary disease (COPD) in patients with poor responses to albuterol. GSK's …

Cilomilast (Ariflo, SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in the treatment of asthma and chronic obstructive pulmonary …

This article reviews available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast (Ariflo, GlaxoSmithKline), a selective PDE4...

2014年12月26日 · Cilomilast (Ariflo™, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the …

A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive …

The oral pharmacokinetics of cilomilast (Ariflo) were investigated in five separate studies in healthy volunteers. Cilomilast was rapidly absorbed, and pharmacokinetics were dose …